PLEASE ANSWER SEPARETELY TO EACH STUDENT WITH DIRECTIONS GIVEN!!! 200 WORDS PER

PLEASE ANSWER SEPARETELY TO EACH STUDENT WITH DIRECTIONS GIVEN!!! 200 WORDS PER EACH STUDENT AND 2 CITATIONS PER STUDENT all separate !
Peer Responses: Your Peer Response should be 200 words and should build upon the author’s first post. You should include at least 2 APA formatted reference/citation that differs from the source in your Original Post. it is not enough to agree or disagree with your peer. Any statement of opinion should be supported by factual data to bolster your point of view. Please answer as if you are talking to the student. Author Cheyenne: Diagnostic companies produce the majority of testing within the healthcare field. These companies will be the ones who are producing the testing to ensure treatment is working towards the desirable outcome. “Indeed many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents” (Morel, McClure, Edwards, et.al, 2016). Diagnostic companies must work at a revenue balance that is of profit rather than that of breaking even or at a loss. Although the approval of a biomarker-based treatment is revolutionary, the creation will ultimately require new assays and possibly new reagents. This is something marketable and profitable for diagnostic companies. They will then be able to produce both traditional assays as well as the revised assays, in turn increasing their income and revenue.
Although diagnostic companies are able to produce a positive revenue from this monumental decision, not everyone is able to benefit from this. Drug developers are now at competition with those producing this treatment due to them not providing their medications to each patient. Although the treatment had to acquire emergency approval through showing positive results, those in the study, and those who will benefit from the treatment, do not require the utilization of the traditional drugs or methods. “The FDA may approve drugs for serious conditions where there is unmet medical need and a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients” (FDA, 2017). The approval of this treatment will curb the utilization of the previously utilized drugs and in turn can cause a financial binding to those drug producing companies. This can be detrimental as the drug producing companies may end up being pushed out if the treatments are considered beneficial and fully approved later on. There is always a push and pull in each decision made within health care. The decision to approve a treatment based upon a biomarker rather than that of the initial origin also has the push and pull decision. The standard of care should continue to be driven to increase as technology and knowledge increases, but also mindful of the companies that are providing for the patients currently. Therefore, if possible, there should be collaboration with industries to allow for the maximum benefit, treatment, and patient outcome. Author Emineh